secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eton Pharmaceuticals, Inc. (ETON)
CIK:        0001710340
Form:       8-K
Filed at:   2025-07-08T23:59:59+00:00
Accession:  0001437749-25-022298
Event type: regulatory
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eton Pharma: FDA accepts NDA for ET-600 desmopressin oral solution; PDUFA Feb 25, 2026
--------------------------------------------------------------------------------

- FDA accepted NDA for ET-600 (desmopressin oral solution) with PDUFA target action date of February 25, 2026.
- Product has patent protection through 2044; expected to be first oral liquid option for pediatric desmopressin dosing.
- CEO states commercial preparation activities already underway for potential launch in Q1 2026.
- Caregivers currently must cut tablets or use unapproved compounding pharmacy liquids for pediatric dosing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710340/000143774925022298/0001437749-25-022298-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710340/000143774925022298/eton20250702_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-022298

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer